The US Company About to Own Juniper Just Surged 25% on the FDA Peptide News. Here's What It Actually Means for Your Australian Protocol.

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. Information on this site does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

This article contains analysis of publicly listed company Hims & Hers Health (NYSE: HIMS) and market developments. Nothing in this article constitutes financial or investment advice. ProtocolHub is a health information platform, not a financial services provider.

Hims & Hers Health (NYSE: HIMS) surged 25% today after the FDA confirmed it will review 12 peptides — including BPC-157, GHK-Cu injectable, and Epitalon — for restoration to legal compounding status. The same company is weeks away from closing a $1.15 billion acquisition of Eucalyptus, the Australian company that owns Juniper and Pilot. If you use either of those clinics for your GLP-1 or hormone protocol, you are about to become a customer of the largest telehealth platform in America. Here is what that convergence means for your access to peptides in Australia — and why the timing matters.

What happened today and why HIMS moved 25%

The FDA published a formal federal notice yesterday confirming it will convene the Pharmacy Compounding Advisory Committee (PCAC) in July to evaluate whether BPC-157, TB-500, GHK-Cu injectable, Epitalon, MOTS-c, and seven other peptides should be restored to Category 1 — the classification that permits legal compounding by licensed US pharmacies.

We covered the full regulatory detail in yesterday's article →

For Hims & Hers, the significance is direct. The company acquired a California peptide manufacturing facility in February 2025 specifically for this moment — to build the infrastructure for legal peptide compounding at scale before the regulatory pathway reopened. Bank of America raised its price target on HIMS to $25 today while maintaining a Neutral rating, noting the FDA development "creates optionality around new potential revenue streams and can help the company repurpose GLP-1 infrastructure for peptide compounding."

Daniel Newman, CEO of The Futurum Group, previously called HIMS "the most likely public company play for peptides at scale." The share price reaction today confirms the market agrees.

The $1.15 billion acquisition that connects all of this to Australia

On February 19, 2026, Hims & Hers announced it would acquire Eucalyptus — Australia's largest digital health platform — for up to $1.15 billion USD. The deal is expected to close in mid-2026. It is pending regulatory approvals.

Eucalyptus is not a name most Australians recognise. But its brands are:

• Juniper — Australia's largest women's weight loss program, 100,000+ patients, GLP-1 focused
• Pilot — Australia's leading men's digital health platform, sexual health, hair loss, weight management
• Kin — reproductive health
• Software — telehealth skincare
• compound — a dedicated compounding pharmacy brand

If you currently use Juniper for Wegovy access or Pilot for any health protocol, you are using a Eucalyptus brand. After mid-2026, you will be using a Hims & Hers brand — the company that just surged 25% on the back of US peptide deregulation and has built a California peptide manufacturing facility in preparation for a restored compounding pathway.

Eucalyptus enters the deal with $450 million AUD in annual revenue run rate, 775,000+ customers, triple-digit year-over-year growth in every quarter of 2025, and the distinction of being the first Australian telehealth business to receive accreditation from the Australian Council on Healthcare Standards.

What Hims & Hers actually wants from this deal — and why peptides are central to it

Hims & Hers has been explicit about its strategic logic. CEO Andrew Dudum described the acquisition as global expansion of a "customer-first, personalised healthcare" model. But the timing — and the peptide facility acquisition in California one year earlier — make the full picture clearer.

Hims & Hers has faced a difficult 2026. It launched a compounded GLP-1 pill at $49, was sued by Novo Nordisk, withdrew the product, and was forced to pivot. The Novo Nordisk lawsuit resolved in a partnership — Hims now distributes Ozempic and Wegovy on its platform at self-pay prices. That stabilised the GLP-1 business but required abandoning the higher-margin compounded version.

Peptides are the replacement category. The company has built the manufacturing infrastructure, positioned in the regulatory debate, and is now acquiring an international network of telehealth clinics — including Australian ones — that can distribute peptide protocols to patients globally once the US compounding pathway is restored.

The 2030 targets Hims & Hers has publicly committed to: $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Achieving those numbers requires new categories beyond GLP-1. Peptides, with a restored US compounding pathway and an international clinic network, are the most credible path to those numbers.

Compare Australian clinics currently offering peptide protocols →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

What this means for Australians using Juniper or Pilot right now

Your access to current services has not changed. The Eucalyptus acquisition has not closed. Juniper and Pilot continue to operate independently until mid-2026 at the earliest. Your existing subscriptions, prescriptions, and treatment plans are unaffected.

The TGA pathway for Australian peptide access is unchanged. As we covered in yesterday's article, Australian access to BPC-157, GHK-Cu injectable, Epitalon, and other Schedule 4 compounds runs through the TGA — not the FDA. The FDA's Category 2 changes do not affect Australian law.

What may change after the acquisition closes:

The combination of a US-listed company's resources with Eucalyptus's established clinical infrastructure and AHPRA-compliant prescribing network creates the conditions for rapid product expansion in Australia. Hims & Hers has demonstrated in the US that it can launch new treatment categories quickly on its platform — hormone health, dermatology, and metabolic health alongside GLP-1.

If the PCAC process results in US compounding access being restored for compounds like BPC-157 and GHK-Cu injectable, the strategic pressure on Hims & Hers to expand peptide offerings internationally — including through Juniper and Pilot in Australia — will be significant. This is not confirmed and it is not imminent. The regulatory and commercial timeline is:

1. PCAC meetings July 2026 — independent scientific review
2. FDA formal rulemaking — several months to over a year after PCAC recommendation
3. US compounding access restored — earliest late 2026, more likely 2027
4. Eucalyptus/Hims integration — mid-2026 close, product expansion timeline unknown
5. Australian peptide offering expansion — speculative, timeline unknown

The practical implication for Australian users of Juniper or Pilot: Watch for new service offerings after the acquisition closes. If Hims & Hers introduces peptide protocols through its platform in the US, the international expansion to Australia via Eucalyptus brands is a logical follow-on — subject to TGA compliance, AHPRA prescribing, and Australian compounding pharmacy access.

The risk picture — what could go wrong

This is a high-stakes corporate story with meaningful execution risks. The ProtocolHub view is that Australians deserve the complete picture, not just the optimistic narrative.

PCAC may not recommend favourably. The PCAC process is supposed to be independent scientific review. Former FDA official Dr. Peter Lurie has publicly stated he doubts the review will be genuinely independent given Kennedy's stated position. If PCAC recommends against restoration for any compound, the US compounding pathway for that compound remains closed.

HIMS stock is still well below its long-term average. Today's 25% move notwithstanding, HIMS trades at approximately $24.29 — well below its 200-day moving average of $38.70. BofA maintained a Neutral rating even while raising the price target. The CFO filed to sell approximately $4.9 million in stock in early April. Peptide optionality is a real tailwind; it does not resolve the company's broader challenge of rebuilding revenue after the compounded GLP-1 withdrawal.

The Eucalyptus acquisition could face regulatory delays. The deal requires regulatory approvals. Australia's ACCC and other relevant bodies have visibility over foreign acquisitions of major domestic healthcare providers. The mid-2026 closing timeline is an estimate.

Australian compounded GLP-1 is banned, not peptides. This is important context. The Australian government banned pharmacy compounding of GLP-1 drugs from October 2024. That does not apply to BPC-157, GHK-Cu, or other Schedule 4 peptides accessed via compounding pharmacy prescription — those pathways remain open. But it signals the TGA is willing to restrict access when it judges safety or commercial conditions warrant it. Any new peptide offering introduced through Eucalyptus brands would need to meet TGA standards.

What Australian peptide users actually need to know

For the ProtocolHub reader whose primary interest is their own health protocol — not the HIMS share price:

Your BPC-157, GHK-Cu, and Epitalon access today runs through AHPRA-registered telehealth practitioners and licensed Australian compounding pharmacies. That pathway is open, unaffected by today's US regulatory developments, and will remain open regardless of how the Eucalyptus acquisition or PCAC process unfolds.

The longer-term implication is that the Australian telehealth clinic landscape is consolidating rapidly. Juniper and Pilot moving into the Hims & Hers ecosystem brings US capital, US peptide manufacturing infrastructure, and US regulatory experience into the Australian market. Whether that makes peptide access easier or more complicated for Australians depends entirely on how Hims & Hers chooses to operate in a TGA-regulated environment — and that is not yet known.

The practical action for now: if BPC-157, GHK-Cu injectable, or Epitalon are relevant to your protocol, access them through the existing AHPRA + compounding pharmacy pathway. Thrive Rx and Phyx have established experience with these compounds. The regulatory and corporate landscape will clarify over the next 12 months.

---

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. Information on this site does not constitute medical advice. Nothing in this article constitutes financial or investment advice.

What to read next

• FDA Peptide Ban — What It Means for Australians — yesterday's full regulatory breakdown
• BPC-157 peptide profile — Australian access, evidence, and prescribing pathway
• GHK-Cu peptide profile — mechanism and Australian compounding access
• Epithalon peptide profile — telomere maintenance and cycle guidance
• GLP-1 in Australia — the complete guide
• Compare Australian peptide and GLP-1 clinics